Evofem Biosciences (NASDAQ:EVFM) vs. Chemomab Therapeutics (NASDAQ:CMMB) Head-To-Head Survey

Chemomab Therapeutics (NASDAQ:CMMB) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.

Valuation and Earnings

This table compares Chemomab Therapeutics and Evofem Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$24.22 million	($0.90)	-1.22
Evofem Biosciences	$11.39 million	0.09	$52.98 million	($0.21)	-0.04

Evofem Biosciences has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Chemomab Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Chemomab Therapeutics and Evofem Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	0	0	2	0	3.00
Evofem Biosciences	0	0	0	0	0.00

Chemomab Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 718.18%. Given Chemomab Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Chemomab Therapeutics is more favorable than Evofem Biosciences.

Profitability

This table compares Chemomab Therapeutics and Evofem Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-101.70%	-76.18%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Summary

Chemomab Therapeutics beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.